{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:16:22Z","timestamp":1791270982186,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005039","name":"Leiden University Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005039","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018748","name":"argenx nv","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004243","name":"Princess Beatrix Foundation for Neuromuscular Diseases","doi-asserted-by":"publisher","award":["W.OR19-13"],"award-info":[{"award-number":["W.OR19-13"]}],"id":[{"id":"10.13039\/501100004243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.isci.2024.111684","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T11:41:17Z","timestamp":1734781277000},"page":"111684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer models"],"prefix":"10.1016","volume":"28","author":[{"given":"Jamie L.","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stine Marie","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap J.","family":"Plomp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhardt","family":"Vankerckhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Kneip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rani","family":"Coppejans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Steyaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Moens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieselot","family":"De Clercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn R.","family":"Tannemaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ulrichts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Silence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silv\u00e8re M.","family":"van der Maarel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana L.E.","family":"Vergoossen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roeland","family":"Vanhauwaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"Verschuuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6082-5042","authenticated-orcid":false,"given":"Maartje G.","family":"Huijbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2024.111684_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3233\/JND-140045","article-title":"The Epidemiology of Neuromuscular Disorders: A Comprehensive Overview of the Literature","volume":"2","author":"Deenen","year":"2015","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.isci.2024.111684_bib2","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.isci.2024.111684_bib3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2024.111684_bib4","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.isci.2024.111684_bib5","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009167","article-title":"The role of MuSK in synapse formation and neuromuscular disease","volume":"5","author":"Burden","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.isci.2024.111684_bib6","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0092-8674(00)81251-9","article-title":"The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in\u00a0vivo","volume":"85","author":"DeChiara","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.isci.2024.111684_bib7","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0896-6273(95)90146-9","article-title":"Receptor tyrosine kinase specific for the skeletal muscle lineage: expression in embryonic muscle, at the neuromuscular junction, and after\u00a0injury","volume":"15","author":"Valenzuela","year":"1995","journal-title":"Neuron"},{"key":"10.1016\/j.isci.2024.111684_bib8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0092-8674(00)81252-0","article-title":"Agrin acts via a MuSK receptor complex","volume":"85","author":"Glass","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.isci.2024.111684_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nn2026","article-title":"MuSK controls where motor axons grow and form synapses","volume":"11","author":"Kim","year":"2008","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.isci.2024.111684_bib10","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nature11348","article-title":"Lrp4 is a retrograde signal for presynaptic differentiation at neuromuscular synapses","volume":"489","author":"Yumoto","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.isci.2024.111684_bib11","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2300453120","article-title":"Structural insights into the assembly of the agrin\/LRP4\/MuSK signaling complex","volume":"120","author":"Xie","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2024.111684_bib12","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.3390\/ijms24043730","article-title":"Clinical and Pathologic Features of Congenital Myasthenic Syndromes Caused by 35 Genes-A Comprehensive Review","volume":"24","author":"Ohno","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2024.111684_bib13","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ana.21371","article-title":"Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction","volume":"63","author":"Cole","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.isci.2024.111684_bib14","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/brain\/aws025","article-title":"Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice","volume":"135","author":"Klooster","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.isci.2024.111684_bib15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.expneurol.2011.04.018","article-title":"Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice","volume":"230","author":"Punga","year":"2011","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.isci.2024.111684_bib16","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1172\/JCI21545","article-title":"Induction of myasthenia by immunization against muscle-specific kinase","volume":"116","author":"Shigemoto","year":"2006","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.isci.2024.111684_bib17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jneuroim.2015.12.016","article-title":"Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity","volume":"291","author":"Huijbers","year":"2016","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.isci.2024.111684_bib18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jneuroim.2012.09.001","article-title":"Antibodies against Wnt receptor of muscle-specific tyrosine kinase in myasthenia gravis","volume":"254","author":"Takamori","year":"2013","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.isci.2024.111684_bib19","doi-asserted-by":"crossref","first-page":"40624","DOI":"10.1074\/jbc.M111.279307","article-title":"Agrin binds to the N-terminal region of Lrp4 protein and stimulates association between Lrp4 and the first immunoglobulin-like domain in muscle-specific kinase (MuSK)","volume":"286","author":"Zhang","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.isci.2024.111684_bib20","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2024.111684_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080695","article-title":"MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters","volume":"8","author":"Koneczny","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2024.111684_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/srep13928","article-title":"Collagen Q and anti-MuSK autoantibody competitively suppress agrin\/LRP4\/MuSK signaling","volume":"5","author":"Otsuka","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2024.111684_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1087532","article-title":"Factors affecting IgG4-mediated complement activation","volume":"14","author":"Oskam","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2024.111684_bib24","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses","volume":"113","author":"Bruhns","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.isci.2024.111684_bib25","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange","volume":"317","author":"van der Neut Kolfschoten","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.isci.2024.111684_bib26","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2016.11.005","article-title":"IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients","volume":"77","author":"Koneczny","year":"2017","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.isci.2024.111684_bib27","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2020635118","article-title":"Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis","volume":"118","author":"Vergoossen","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2024.111684_bib28","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1212\/NXI.0000000000000547","article-title":"MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity","volume":"6","author":"Huijbers","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.isci.2024.111684_bib29","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1113\/jphysiol.2013.270207","article-title":"Muscle-specific kinase (MuSK) autoantibodies suppress the MuSK pathway and ACh receptor retention at the mouse neuromuscular junction","volume":"592","author":"Ghazanfari","year":"2014","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.isci.2024.111684_bib30","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1111\/ejn.16347","article-title":"Change of voltage-gated sodium channel repertoire in skeletal muscle of a MuSK myasthenia gravis mouse model","volume":"59","author":"Butenko","year":"2024","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.isci.2024.111684_bib31","doi-asserted-by":"crossref","first-page":"e34375","DOI":"10.7554\/eLife.34375","article-title":"Preserving neuromuscular synapses in ALS by stimulating MuSK with a therapeutic agonist antibody","volume":"7","author":"Cantor","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.isci.2024.111684_bib32","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41586-021-03672-3","article-title":"Mechanism of disease and therapeutic rescue of Dok7 congenital myasthenia","volume":"595","author":"Oury","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.isci.2024.111684_bib33","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.nbd.2018.12.002","article-title":"Muscle specific kinase (MuSK) activation preserves neuromuscular junctions in the diaphragm but is not sufficient to provide a functional benefit in the SOD1(G93A) mouse model of ALS","volume":"124","author":"Sengupta-Ghosh","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.isci.2024.111684_bib34","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrd.2018.75","article-title":"The promise and challenges of immune agonist antibody development in cancer","volume":"17","author":"Mayes","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.isci.2024.111684_bib35","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200147","article-title":"IgG1-3 MuSK Antibodies Inhibit AChR Cluster Formation, Restored by SHP2 Inhibitor, Despite Normal MuSK, DOK7, or AChR Subunit Phosphorylation","volume":"10","author":"Cao","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.isci.2024.111684_bib36","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1212\/NXI.0000000000000645","article-title":"SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody","volume":"7","author":"Huda","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.isci.2024.111684_bib37","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1038\/s41598-023-32641-1","article-title":"Development and characterization of agonistic antibodies targeting the Ig-like 1 domain of MuSK","volume":"13","author":"Lim","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2024.111684_bib38","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1468-1331.2007.01870.x","article-title":"Clinical and experimental features of MuSK antibody positive MG in Japan","volume":"14","author":"Ohta","year":"2007","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.isci.2024.111684_bib39","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.20061","article-title":"Detection and characterization of MuSK antibodies in seronegative myasthenia gravis","volume":"55","author":"McConville","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.isci.2024.111684_bib40","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00038-019-01298-x","article-title":"Cost-effectiveness of precision medicine: a scoping review","volume":"64","author":"Kasztura","year":"2019","journal-title":"Int. J. Public Health"},{"key":"10.1016\/j.isci.2024.111684_bib41","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","article-title":"Anti-MuSK antibodies: correlation with myasthenia gravis severity","volume":"67","author":"Bartoccioni","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.isci.2024.111684_bib42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1474-4422(21)00463-4","article-title":"Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders","volume":"21","author":"Verschuuren","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.isci.2024.111684_bib43","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s40478-022-01454-0","article-title":"Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy","volume":"10","author":"Fichtner","year":"2022","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.isci.2024.111684_bib44","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2408324121","article-title":"Agonist antibody to MuSK protects mice from MuSK myasthenia gravis","volume":"121","author":"Oury","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2024.111684_bib45","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.isci.2024.111684_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ado7189","article-title":"ARGX-119 is an agonist antibody for human MuSK that reverses disease relapse in a mouse model of congenital myasthenic syndrome","volume":"16","author":"Vanhauwaert","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2024.111684_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2022.114300","article-title":"Proteolytic ectodomain shedding of muscle-specific tyrosine kinase in myasthenia gravis","volume":"361","author":"Mori","year":"2023","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.isci.2024.111684_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103032","article-title":"Recent insights into neuromuscular junction biology in Duchenne muscular dystrophy: Impacts, challenges, and\u00a0opportunities","volume":"61","author":"Ng","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.isci.2024.111684_bib49","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00018-014-1663-7","article-title":"Recovery of altered neuromuscular junction morphology and muscle function in mdx mice after injury","volume":"72","author":"Pratt","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.isci.2024.111684_bib50","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1111\/ejn.13249","article-title":"Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular dystrophy mouse models","volume":"43","author":"van der Pijl","year":"2016","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.isci.2024.111684_bib51","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/labinvest.3700163","article-title":"Reduced expression of nicotinic AChRs in myotubes from spinal muscular atrophy I patients","volume":"84","author":"Arnold","year":"2004","journal-title":"Lab. Invest."},{"key":"10.1016\/j.isci.2024.111684_bib52","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1080\/14728222.2017.1369960","article-title":"Agrin-LRP4-MuSK signaling as a therapeutic target for myasthenia gravis and other neuromuscular disorders","volume":"21","author":"Ohno","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.isci.2024.111684_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22158015","article-title":"Activation of Muscle-Specific Kinase (MuSK) Reduces Neuromuscular Defects in the Delta7 Mouse Model of Spinal Muscular Atrophy (SMA)","volume":"22","author":"Feng","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2024.111684_bib54","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1111\/j.1460-9568.2007.05438.x","article-title":"Severely impaired neuromuscular synaptic transmission causes muscle weakness in the Cacna1a-mutant mouse rolling Nagoya","volume":"25","author":"Kaja","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.isci.2024.111684_bib55","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.4049\/jimmunol.169.11.6570","article-title":"Split tolerance in a novel transgenic model of autoimmune myasthenia gravis","volume":"169","author":"Stacy","year":"2002","journal-title":"J.\u00a0Immunol."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004224029110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004224029110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:59:01Z","timestamp":1780088341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004224029110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2589004224029110"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2024.111684","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.08.01.606156","asserted-by":"object"}]},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer models","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2024.111684","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111684"}}